NASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Free DNLI Stock Alerts $15.99 -0.01 (-0.06%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$15.48▼$16.2850-Day Range$15.99▼$23.3552-Week Range$15.45▼$33.31Volume3.06 million shsAverage Volume1.19 million shsMarket Capitalization$2.28 billionP/E RatioN/ADividend YieldN/APrice Target$41.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Denali Therapeutics alerts: Email Address Denali Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside157.8% Upside$41.22 Price TargetShort InterestBearish8.39% of Float Sold ShortDividend StrengthN/ASustainability-0.84Upright™ Environmental ScoreNews Sentiment0.72Based on 5 Articles This WeekInsider TradingSelling Shares$2.22 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.62) to ($2.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.84 out of 5 starsMedical Sector207th out of 909 stocksBiological Products, Except Diagnostic Industry27th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.39% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 8.Change versus previous monthShort interest in Denali Therapeutics has recently increased by 12.29%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDenali Therapeutics has received a 74.49% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for physiological diseases ", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Denali Therapeutics is -0.84. Previous Next 3.2 News and Social Media Coverage News SentimentDenali Therapeutics has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Denali Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for DNLI on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days.MarketBeat Follows13 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 18% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,218,802.00 in company stock.Percentage Held by InsidersOnly 7.90% of the stock of Denali Therapeutics is held by insiders.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.62) to ($2.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -14.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -14.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Denali Therapeutics Stock (NASDAQ:DNLI)Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More DNLI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DNLI Stock News HeadlinesApril 19, 2024 | insidertrades.comVicki L. Sato Sells 1,666 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) StockApril 3, 2024 | insidertrades.comDenali Therapeutics Inc. (NASDAQ:DNLI) Director Steve E. Krognes Sells 92,500 SharesApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 20, 2024 | nasdaq.comOversold Conditions For Denali Therapeutics (DNLI)April 17, 2024 | msn.comDenali Therapeutics (DNLI) Price Target Decreased by 5.45% to 42.01April 8, 2024 | tmcnet.comFlagship Appoints Amy O'Shea as CEO-Partner and Chief Executive Officer of Invaio SciencesMarch 22, 2024 | msn.comDenali Therapeutics files to sell 29.29M shares of common stock for holdersMarch 19, 2024 | finance.yahoo.comFurther weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 17, 2024 | finance.yahoo.comDNLI Apr 2024 12.500 putMarch 16, 2024 | finance.yahoo.comDNLI Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comDNLI Apr 2024 17.500 putMarch 1, 2024 | markets.businessinsider.comStrong Growth and Value Potential Justify Buy Rating for Denali Therapeutics Despite DilutionFebruary 29, 2024 | markets.businessinsider.comGoldman Sachs Maintains Buy Rating for Denali Therapeutics: Here's What You Need To KnowFebruary 29, 2024 | markets.businessinsider.comBuy Rating Affirmed on Denali Therapeutics Amid Promising DNL310 Progress and ETV Technology PotentialFebruary 28, 2024 | markets.businessinsider.comStrong Buy Rating for Denali Therapeutics: Financial Stability and Promising Clinical AdvancementsFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Denali Therapeutics on Strong Pipeline and Extended Cash RunwayFebruary 28, 2024 | markets.businessinsider.com4 Analysts Assess Denali Therapeutics: What You Need To KnowFebruary 28, 2024 | marketwatch.comDenali Therapeutics Shares Rise 19% After $500M FinancingFebruary 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS) and Denali Therapeutics (DNLI)February 27, 2024 | finanznachrichten.deDenali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsFebruary 27, 2024 | msn.comCalidi Biotherapeutics, Minerva Neurosciences and Janux among healthcare moversFebruary 27, 2024 | msn.comDenali spikes after $500M private placementFebruary 27, 2024 | finance.yahoo.comDenali Therapeutics Inc (DNLI) Reports Full Year and Q4 2023 Financial ResultsFebruary 27, 2024 | globenewswire.comDenali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business HighlightsFebruary 27, 2024 | globenewswire.comDenali Therapeutics Announces $500 million Private Placement Equity FinancingFebruary 23, 2024 | markets.businessinsider.comBuy Rating on Denali Therapeutics: Anticipating Accelerated FDA Approval with CSF HS Biomarker BreakthroughSee More Headlines Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/22/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:DNLI CUSIPN/A CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees445Year Founded2015Price Target and Rating Average Stock Price Target$41.22 High Stock Price Target$95.00 Low Stock Price Target$28.00 Potential Upside/Downside+157.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-145,220,000.00 Net Margins-36.51% Pretax Margin-43.93% Return on Equity-13.50% Return on Assets-11.38% Debt Debt-to-Equity RatioN/A Current Ratio13.65 Quick Ratio13.65 Sales & Book Value Annual Sales$330.53 million Price / Sales6.90 Cash FlowN/A Price / Cash FlowN/A Book Value$7.42 per share Price / Book2.15Miscellaneous Outstanding Shares142,540,000Free Float131,279,000Market Cap$2.28 billion OptionableOptionable Beta1.33 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Ryan J. Watts Ph.D. (Age 48)Co-Founder, President, CEO & Director Comp: $1.04MDr. Alexander O. Schuth M.D. (Age 51)Co-Founder, CFO, COO & Secretary Comp: $737.2kDr. Marc Tessier-Lavigne Ph.D. (Age 64)Co-Founder & Independent Director Comp: $58.23kDr. Carole Ho M.D. (Age 51)Chief Medical Officer & Head of Development Comp: $737.2kMr. Tyler M. Nielsen (Age 46)Senior Vice President of Corporate Finance Dr. Dana AndersenChief Technical and Manufacturing OfficerMr. Joe Lewcock Ph.D.Chief Scientific OfficerDr. Laura HansenVice President of Investor RelationsMr. Chris WalshGeneral CounselMr. Mark RowenVice President of Corporate DevelopmentMore ExecutivesKey CompetitorsCG OncologyNASDAQ:CGONVericelNASDAQ:VCELImmunocoreNASDAQ:IMCRBeam TherapeuticsNASDAQ:BEAMKymera TherapeuticsNASDAQ:KYMRView All CompetitorsInsiders & InstitutionsWasatch Advisors LPBought 90,369 shares on 4/18/2024Ownership: 0.289%Vicki L SatoSold 1,666 sharesTotal: $30,471.14 ($18.29/share)Los Angeles Capital Management LLCBought 9,054 shares on 4/5/2024Ownership: 0.040%Steve E KrognesSold 92,500 sharesTotal: $1.90 M ($20.50/share)PNC Financial Services Group Inc.Bought 807 shares on 3/22/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions DNLI Stock Analysis - Frequently Asked Questions Should I buy or sell Denali Therapeutics stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DNLI shares. View DNLI analyst ratings or view top-rated stocks. What is Denali Therapeutics' stock price target for 2024? 8 brokers have issued 12-month target prices for Denali Therapeutics' shares. Their DNLI share price targets range from $28.00 to $95.00. On average, they expect the company's stock price to reach $41.22 in the next twelve months. This suggests a possible upside of 157.8% from the stock's current price. View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts. How have DNLI shares performed in 2024? Denali Therapeutics' stock was trading at $21.46 at the beginning of 2024. Since then, DNLI shares have decreased by 25.5% and is now trading at $15.99. View the best growth stocks for 2024 here. Are investors shorting Denali Therapeutics? Denali Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 9,410,000 shares, an increase of 12.3% from the March 15th total of 8,380,000 shares. Based on an average trading volume of 1,180,000 shares, the short-interest ratio is currently 8.0 days. Approximately 8.4% of the shares of the stock are sold short. View Denali Therapeutics' Short Interest. When is Denali Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our DNLI earnings forecast. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) announced its earnings results on Tuesday, February, 27th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by $0.05. Denali Therapeutics had a negative net margin of 36.51% and a negative trailing twelve-month return on equity of 13.50%. During the same period last year, the firm posted ($0.75) earnings per share. What ETFs hold Denali Therapeutics' stock? ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI) and BNY Mellon Innovators ETF (BKIV).Principal Healthcare Innovators ETF (BTEC). What is Ryan Watts' approval rating as Denali Therapeutics' CEO? 1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG). When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager. Who are Denali Therapeutics' major shareholders? Denali Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wasatch Advisors LP (0.29%) and Los Angeles Capital Management LLC (0.04%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato. View institutional ownership trends. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:DNLI) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.